143 results
DEF 14A
MREO
Mereo Biopharma Group Plc
24 Apr 24
Definitive proxy
7:30am
report and accounts for the year ended December 31, 2023, together with the directors’ report and independent auditor’s report thereon, be received … to instruct Citibank, N.A. how to vote your ADSs.
Who counts the votes?
Link Group has been engaged as our independent agent to tabulate shareholder votes
10-K
2023 FY
MREO
Mereo Biopharma Group Plc
27 Mar 24
Annual report
5:20pm
to rely, on third parties, including independent investigators and CROs, to conduct our clinical trials. If these CROs do not successfully carry out … of alvelestat versus placebo in approximately 220 patients with AATD-LD with two independent primary endpoints to support applications for full marketing
10-K
2023 FY
EX-10.30
MREO
Mereo Biopharma Group Plc
27 Mar 24
Annual report
5:20pm
an independent public accounting firm of nationally recognized standing designated by Mereo, at reasonable times during normal business hours and upon … shall be independent contractors and that the relationship between the Parties shall not constitute a partnership, joint venture, or agency
10-K
2023 FY
EX-19.1
MREO
Mereo Biopharma Group Plc
27 Mar 24
Annual report
5:20pm
until the information becomes public or is no longer material.
Transactions that may be necessary or justifiable for independent reasons
10-K
2023 FY
EX-23.1
MREO
Mereo Biopharma Group Plc
27 Mar 24
Annual report
5:20pm
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration
S-8
EX-23.2
h6a1oamodf8w5 wlw
23 Jan 24
Registration of securities for employees
4:16pm
S-8
urmqnl
23 Jan 24
Registration of securities for employees
4:16pm
6-K
EX-99.1
bcgb30 1vz18x3gunb
16 Nov 23
Current report (foreign)
7:01am
6-K
EX-99.1
owix4qcg apsu
23 Oct 23
Mereo BioPharma Reports on Recent Program Developments and Provides Financial Update
4:08pm
6-K
cf12i19d2h3
20 Sep 23
Current report (foreign)
4:03pm
6-K
EX-16.1
ad0 7cq2zqrga
20 Sep 23
Current report (foreign)
4:03pm
6-K
EX-99.3
u4aqrxcoz ehf7
7 Sep 23
Current report (foreign)
7:37am
6-K
65jlpjnit2zt
22 May 23
Current report (foreign)
4:15pm
6-K
hr15c
10 Nov 22
Current report (foreign)
4:06pm
6-K
EX-99.2
mvn6i
28 Oct 22
Mereo BioPharma Reaches Cooperation Agreement with Rubric Capital Management
7:11am
6-K
EX-99.1
thcv0
21 Oct 22
Mereo BioPharma Files Shareholder Circular for Upcoming General Meeting
7:06am
6-K
EX-99.2
g5i7ue8x
21 Oct 22
Mereo BioPharma Files Shareholder Circular for Upcoming General Meeting
7:06am
6-K
EX-99.1
1nvsjd3 s3
3 Oct 22
Mereo BioPharma Confirms Receipt of a Valid Notice Requiring it to Convene a General Meeting of Shareholders
5:43pm
6-K
EX-99.1
0f2j0 0tkrsdwsjnt7b
31 Aug 22
Letter Reiterates Mereo’s Updated Strategic Plan to Maximize Value for All Shareholders and Corrects Rubric’s Assumptions
7:57am
6-K
EX-99.1
h3bjz
22 Aug 22
Notifies Rubric of Certain Deficiencies in its Notice Purporting to Call a General Meeting of Shareholders
4:06pm